{"id":117573,"date":"2026-09-04T12:24:12","date_gmt":"2026-09-04T12:24:12","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/117573\/"},"modified":"2026-09-04T12:24:12","modified_gmt":"2026-09-04T12:24:12","slug":"chinas-hutchmed-inks-1-3-b-deal-with-gsk-for-kras-egfr-antibody-conjugate-cancer-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/117573\/","title":{"rendered":"China&#8217;s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy"},"content":{"rendered":"<p>\t\t\t\t\t\tChina&#8217;s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy<\/p>\n<p class=\"float-left\">September 4, 2026 | Friday | News<\/p>\n<p>\t\t\t\t\t\t\tHutchmed Limited will be responsible for the global phase I development programme&#13;<\/p>\n<p>\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/09\/screenshot_4_9_2026_17626_www_bing_com-28318.jpeg\" class=\"img-fluid w-100 pl-5 pr-5\" alt=\"image credit- shutterstock\"\/><\/p>\n<p class=\"mt-3 text-center\">image credit- shutterstock<\/p>\n<p style=\"text-align: justify;\">Hutchmed (China) has announced that its subsidiary,\u00a0Hutchmed Limited has entered into an exclusive development and license agreement with a subsidiary of GSK plc, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.<\/p>\n<p style=\"text-align: justify;\">Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a $110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of $1.295 billion, and royalties on net\u00a0sales.<\/p>\n<p style=\"text-align: justify;\">This first-in-class drug candidate, an Antibody-Targeted Therapy Conjugate (ATTC), comprises a highly selective and potent Kirsten rat sarcoma (KRAS) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody. An ATTC enables tumour-selective activity of potent, cell-killing payloads by leveraging antibody-guided therapy.<\/p>\n<p style=\"text-align: justify;\">Colorectal, lung, and pancreatic cancers have the highest incidence of patients with KRAS-altered tumours, who often lack a safe and durable KRAS therapy. HMPL-A830 is designed to address this need by delivering a KRAS inhibitor directly to EGFR-expressing tumours, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.<\/p>\n<p style=\"text-align: justify;\">Under the terms of the agreement, Hutchmed Limited will be responsible for the global phase I development programme, which is expected to start in the second half of 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"China&#8217;s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy September 4, 2026 | Friday&hellip;\n","protected":false},"author":2,"featured_media":117574,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[1852,255,36486,20785,44044,47945],"class_list":["post-117573","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-cancer","tag-china","tag-egfr","tag-gsk","tag-hutchmed","tag-kras"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117212758980846497","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=117573"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117573\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/117574"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=117573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=117573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=117573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}